Ea9181 A Phase III Randomized Trial Of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy Or Blinatumomab For Newly Diagnosed Bcr-Abl-Positive Acute Lymphoblastic Leukemia In Adults
Posted Date: Jul 13, 2021
- Investigator: Emily Curran
- Specialties: Cancer, Leukemia, Oncology
- Type of Study: Drug
This trial will compare the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. Efficacy will be measured by overall survival.
Criteria:
Patient Must Have Bcr-Abl1 Positive Disease. Total Bilirubin =< 3 Mg/Dl. Estimated Creatinine Clearance > 45 Mg/Min. Patients Must Be Class 2B Or Better. Patient Must Not Have Received Chemotherapy For B-All. No Active Central Nervous System (Cns) Involvement By Leukemic Blasts. No Active Concomitant Malignancy.
Keywords:
Phase 3, Leukemia
For More Information:
Uc Cancer Center
5135847698
cancer@uchealth.com